Market Overview

NuPathe Announces Allowance of U.S. Patent Application for NP202


NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 11/183,232 entitled "Drug Containing Implants and Methods of Use Thereof." This application relates to a biodegradable polymer implant as well as novel methods of treating schizophrenia, bipolar disorder and other specified psychiatric disorders with the implant by delivering therapeutic levels of risperidone, 9-hydroxy-risperidone, or haloperidol for 20 to 190 days.

Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection through January 2025 for NP202, NuPathe's long-term biodegradable risperidone implant for the treatment of schizophrenia and bipolar disorder. NuPathe has additional licensed patent applications pending in the U.S. and other territories for NP202.

Posted-In: News FDA


Related Articles (PATH)

View Comments and Join the Discussion!